Janux Therapeutics (JANX) Gains from Investment Securities (2021 - 2026)

Janux Therapeutics (JANX) has 6 years of Gains from Investment Securities data on file, last reported at $1.3 million in Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $1.3 million, down 55.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.1 million (down 1.48% YoY), and the FY2025 annual result was $9.5 million, up 2853.26% from the prior year.
• Gains from Investment Securities eased to $1.3 million in Q1 2026 per JANX's latest filing, from $7.0 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $10.0 million in Q3 2025 and troughed at -$7.2 million in Q4 2024.
• A 5-year average of $2.4 million and a median of $1.3 million in 2026 frame the typical range for Gains from Investment Securities.
• The sharpest annual moves came in 2022 and 2023: Gains from Investment Securities tumbled 5385.71% in 2022, then surged 2769.49% in 2023.
• A 5-year view of Gains from Investment Securities shows it stood at $586000.0 in 2022, then increased by 29.52% to $759000.0 in 2023, then plunged by 1044.14% to -$7.2 million in 2024, then surged by 197.08% to $7.0 million in 2025, then slumped by 80.8% to $1.3 million in 2026.
• Business Quant data shows JANX's Gains from Investment Securities at $1.3 million in Q1 2026, $7.0 million in Q4 2025, and $10.0 million in Q3 2025.